Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast

The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. In the last 30 years, only two immunotherapies have been approved in this indication: Genentech’s Tecentriq in 2019 and AstraZeneca’s Imfinzi in 2020 for treatment of extensive-stage disease across the G7 markets. Despite approval of these drugs, a substantial unmet need remains for better therapeutic options, especially in the later lines of therapy. However, the modest late-phase pipeline for SCLC is set to boost the market—namely, with Amgen’s bispecific T-cell engager (BiTE) tarlatamab and Daiichi’s antibody-drug conjugate (ADC) ifinatamab deruxtecan. Nevertheless, considerable commercial potential remains for targeted agents that treat the underserved relapsed/refractory SCLC population.

Questions Answered

  • What are interviewed experts’ insights on the current treatment options for SCLC?
  • How large are the drug-treatable SCLC populations, and how will drug-treatment rates change over time?
  • How will key emerging therapies shape the SCLC market over the 10-year forecast period?
  • What key factors are driving or constraining market growth?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents